BR112022010774A2 - Uso de nucleossomos livres de células como biomarcadores - Google Patents
Uso de nucleossomos livres de células como biomarcadoresInfo
- Publication number
- BR112022010774A2 BR112022010774A2 BR112022010774A BR112022010774A BR112022010774A2 BR 112022010774 A2 BR112022010774 A2 BR 112022010774A2 BR 112022010774 A BR112022010774 A BR 112022010774A BR 112022010774 A BR112022010774 A BR 112022010774A BR 112022010774 A2 BR112022010774 A2 BR 112022010774A2
- Authority
- BR
- Brazil
- Prior art keywords
- biomarkers
- cell
- free nucleosomes
- nucleosomes
- free
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942596P | 2019-12-02 | 2019-12-02 | |
| US202063088408P | 2020-10-06 | 2020-10-06 | |
| PCT/EP2020/084328 WO2021110776A1 (en) | 2019-12-02 | 2020-12-02 | Use of cell free nucleosomes as biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010774A2 true BR112022010774A2 (pt) | 2022-08-23 |
Family
ID=73698838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010774A BR112022010774A2 (pt) | 2019-12-02 | 2020-12-02 | Uso de nucleossomos livres de células como biomarcadores |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230003735A1 (https=) |
| EP (2) | EP4435431A3 (https=) |
| JP (2) | JP7693670B2 (https=) |
| KR (1) | KR102930652B1 (https=) |
| CN (1) | CN114829939B (https=) |
| AU (1) | AU2020395504A1 (https=) |
| BR (1) | BR112022010774A2 (https=) |
| CA (1) | CA3163181A1 (https=) |
| ES (1) | ES2988371T3 (https=) |
| IL (1) | IL293342B1 (https=) |
| MX (1) | MX2022006655A (https=) |
| PL (1) | PL4070111T3 (https=) |
| TW (1) | TWI902730B (https=) |
| WO (1) | WO2021110776A1 (https=) |
| ZA (1) | ZA202205916B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2820129A1 (en) * | 2012-03-02 | 2015-01-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| JP2024542996A (ja) | 2021-10-29 | 2024-11-19 | ベルジアン ボリション エスアールエル | 均一系免疫アッセイ法 |
| GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
| EP4490323A1 (en) | 2022-03-11 | 2025-01-15 | Belgian Volition SRL | Differential diagnosis method |
| WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
| EP4639173A1 (en) * | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Calibration |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319376D0 (en) | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| GB0413732D0 (en) * | 2004-06-13 | 2004-07-21 | Chroma Therapeutics Ltd | Histone modification |
| ATE534908T1 (de) * | 2009-08-03 | 2011-12-15 | Universitaetsklinikum Freiburg | Verfahren und verbindungen zur diagnose und behandlung von krebs |
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| GB201115099D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes |
| PT2788767T (pt) | 2011-12-07 | 2017-12-06 | Belgian Volition Sprl | Método de detecção de adutos de nucleosoma |
| EP2820129A1 (en) * | 2012-03-02 | 2015-01-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9388213B2 (en) * | 2012-09-10 | 2016-07-12 | The Rockefeller University | Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof |
| CN107209190B (zh) * | 2014-10-29 | 2021-07-16 | 比利时意志有限责任公司 | 用于富集循环肿瘤dna的方法 |
| GB201511512D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell-free nucleosomes as biomarkers |
| GB201511542D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell free nucleosomes as biomarkers |
| GB201518665D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
| GB201518674D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for detecting nuleosomes containing histone modifications and variants |
| ES2960550T3 (es) * | 2018-03-01 | 2024-03-05 | Epicypher Inc | Cuantificación de modificaciones de nucleosoma utilizando nucleosomas recombinantes definidos químicamente |
-
2020
- 2020-12-02 IL IL293342A patent/IL293342B1/en unknown
- 2020-12-02 AU AU2020395504A patent/AU2020395504A1/en active Pending
- 2020-12-02 CN CN202080083887.9A patent/CN114829939B/zh active Active
- 2020-12-02 MX MX2022006655A patent/MX2022006655A/es unknown
- 2020-12-02 EP EP24193398.5A patent/EP4435431A3/en active Pending
- 2020-12-02 BR BR112022010774A patent/BR112022010774A2/pt unknown
- 2020-12-02 CA CA3163181A patent/CA3163181A1/en active Pending
- 2020-12-02 US US17/781,652 patent/US20230003735A1/en active Pending
- 2020-12-02 PL PL20819704.6T patent/PL4070111T3/pl unknown
- 2020-12-02 TW TW109142306A patent/TWI902730B/zh active
- 2020-12-02 EP EP20819704.6A patent/EP4070111B1/en active Active
- 2020-12-02 ES ES20819704T patent/ES2988371T3/es active Active
- 2020-12-02 WO PCT/EP2020/084328 patent/WO2021110776A1/en not_active Ceased
- 2020-12-02 JP JP2022532782A patent/JP7693670B2/ja active Active
- 2020-12-02 KR KR1020227022609A patent/KR102930652B1/ko active Active
-
2022
- 2022-05-27 ZA ZA2022/05916A patent/ZA202205916B/en unknown
-
2025
- 2025-06-05 JP JP2025093848A patent/JP2025124845A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4070111A1 (en) | 2022-10-12 |
| MX2022006655A (es) | 2022-09-07 |
| KR102930652B1 (ko) | 2026-02-25 |
| TW202134654A (zh) | 2021-09-16 |
| IL293342B1 (en) | 2026-01-01 |
| AU2020395504A1 (en) | 2022-06-23 |
| ES2988371T3 (es) | 2024-11-20 |
| JP7693670B2 (ja) | 2025-06-17 |
| CA3163181A1 (en) | 2021-06-10 |
| US20230003735A1 (en) | 2023-01-05 |
| EP4070111B1 (en) | 2024-08-21 |
| KR20220110794A (ko) | 2022-08-09 |
| JP2025124845A (ja) | 2025-08-26 |
| JP2023503379A (ja) | 2023-01-27 |
| PL4070111T3 (pl) | 2025-02-03 |
| EP4435431A3 (en) | 2024-10-16 |
| EP4435431A2 (en) | 2024-09-25 |
| CN114829939B (zh) | 2025-10-21 |
| CN114829939A (zh) | 2022-07-29 |
| IL293342A (en) | 2022-07-01 |
| WO2021110776A1 (en) | 2021-06-10 |
| TWI902730B (zh) | 2025-11-01 |
| ZA202205916B (en) | 2024-09-25 |
| EP4070111C0 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010774A2 (pt) | Uso de nucleossomos livres de células como biomarcadores | |
| EP4567127A3 (en) | Methods for determining a location of a biological analyte in a biological sample | |
| EP4234689A3 (en) | Split inteins with exceptional splicing activity | |
| MX356986B (es) | Metodo para detectar aductos de nucleosomas. | |
| BR112016017418A8 (pt) | uso de copolímeros | |
| MX2021008376A (es) | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. | |
| MX391068B (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina. | |
| ECSP15049909A (es) | Composiciones y métodos para alterar la señalización del segundo mensajero | |
| CO2022004797A2 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| BR112017018276A2 (pt) | ?composição que compreende peptidase e biotensoativo e seu uso? | |
| CO7151531A2 (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| MX2013010475A (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
| TR201906354T4 (tr) | Bi̇r hareketli̇ mobi̇lya parçasi i̇çi̇n tahri̇k ci̇hazi | |
| UA110470C2 (ru) | Антидот антикоагулянта | |
| EP4279762A3 (en) | Eddy current brake configurations | |
| CL2018003838S1 (es) | Botella. | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| CO2018005755A2 (es) | Mezcla hemostática de fibras cortas y largas basadas en celulosa | |
| MX2017013013A (es) | Estireno funcionalizado con [bis(trihidrocarbilsilil)aminosililo] y un metodo para su preparacion. | |
| NZ733127A (en) | Tapered precision blade electrosurgical instrument | |
| MX2018008383A (es) | Inmunoterapia contra el cáncer mediada por superantígeno mejorada por inmunopotenciador. | |
| BR112018006446A2 (pt) | composições lubrificantes e métodos para uso das mesmas | |
| CL2020003034A1 (es) | Agonistas de tlr7 | |
| BR112018015343A2 (pt) | oxidação de amido | |
| BR112016001229A2 (pt) | Composição de revestimento aquosa com durabilidade melhorada |